Clinical trials: Inhalation
Perennial Allergic Rhinitis, Obstructive Sleep Apnea
The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
This is a Phase 4 randomized, placebo-controlled, parallel-group, single-center, double-blind study to evaluate the effects of mometasone furoate nasal spray (MFNS) in subjects with Sleep-disordered Breathing (SDB) associated…
- Conditions
- Perennial Allergic Rhinitis, Obstructive Sleep Apnea, Sleep Disorder
- Trial name
- NCT00359216
- Testing
- Mometasone furoate nasal spray
- Volunteers
- 30 people
- Sponsor
- Organon and Co
Pulmonary Arterial Hypertension
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.
- Trial name
- INTREPID (NCT01557647)
- Testing
- Inhaled treprostinil
- Sponsor
- United Therapeutics
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Pulmonary Disease, Chronic Obstructive
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00144911
- Testing
- Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
- Where
- 97 sites in United States, Canada
- Volunteers
- 740 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to compare the bronchodilator efficacy and safety of once daily dosing of tiotropium inhalation capsules (18 ?g) and Atrovent? MDI (2 puffs of ipratropium bromide 20 ?g four times daily) in patients…
- Trial name
- NCT00239434
- Testing
- tiotropium inhalation powder capsule, ipratropium bromide Metered Dose Inhaler
- Where
- 6 sites in China
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients
To investigate the dose response following single inhalation of Ba 679 BR inhalation powder in COPD patients using pulmonary functions as indicators, and to compare data obtained with overseas study findings
- Trial name
- NCT02172352
- Testing
- Ba 679 BR low dose, Ba 679 BR middle dose, Ba 679 BR high dose
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Asthma
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)
This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) versus MF for 26 weeks.
- Trial name
- NCT00383552
- Testing
- Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID, Mometasone Furoate MDI (MF MDI), Formoterol Fumarate 10 mcg
- Volunteers
- 746 people
- Sponsor
- Organon and Co
Asthma
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA134a propelled Metered Dose Inhaler (MDI) (E004), using a stable isotope deuterium-labeled epinephrine…
- Trial name
- NCT01255709
- Testing
- Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431287
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 240 sites in United States, Austria and 22 more
- Volunteers
- 2,539 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a…
- Trial name
- NCT00043316
- Testing
- interferon gamma-1b
- Where
- 17 sites in United States
- Volunteers
- 66 people
- Sponsor
- InterMune
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Asthma
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus
The purposes of this study is to compare the test products Salmeterol/fluticasone Easyhaler with marketed product Seretide Diskus in terms of the drug absorbed into the blood stream
- Trial name
- NCT02162485
- Testing
- Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus
- Where
- Finland
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
COPD
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
- Trial name
- NCT07116915
- Testing
- HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension, Moxifloxacin Hydrochloride Tablets
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Sleep Apnea Syndromes
Comparison of Sleep Disordered Breathing Events Detected by the CPAP Device "prismaLine" With Polysomnography
Evaluation of residual sleep disordered breathing (SDB) under continuous positive airway pressure (CPAP) therapy with comparison of the automatic detected SDB event indices from CPAP machines with manual scored polysomnography…
- Trial name
- NCT04407949
- Testing
- CPAP Treatment
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Pulmonary Disease, Chronic Obstructive
12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
Determine the effect of 12-week treatment with inhaled tiotropium bromide on lung function and static lung volumes, correlate this effect with dyspnoea in COPD patients.
- Trial name
- NCT02172378
- Testing
- Tiotropium inhalation capsules
- Volunteers
- 116 people
- Sponsor
- Boehringer Ingelheim
Asthma
The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
This study will investigate the additive effect of montelukast (MK0476) taken along with inhaled beclomethasone versus inhaled beclomethasone alone.
- Trial name
- NCT00911547
- Testing
- montelukast sodium, beclomethasone
- Volunteers
- 642 people
- Sponsor
- Organon and Co
Anaesthesia
General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.
The purpose of this study is to evaluate the quantity of propofol administered with Xenon in two inspiratory concentrations, to maintain comparable depth of anaesthesia during the maintenance period of general anaesthesia.
- Trial name
- NCT00919126
- Testing
- Xenon, Medical Air in Oxygen
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 102 people
- Sponsor
- Air Liquide SA
Healthy
Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers
1. To compare the systemic drug exposure of 100 μg Serevent ® Diskus ® with that of 50 μg Serevent ® MDI with sufficient precision so that in combination with a second trial it can be demonstrated that the systemic drug exposure…
- Trial name
- NCT02254226
- Testing
- Salmeterol Diskus low, Salmeterol Diskus high, Salmeterol MDI low
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease(COPD)
A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to assess the long term safety and efficacy of AeriSeal System treatment administered at up to 4 subsegments during a single treatment session for lung volume reduction in patients with advanced…
- Conditions
- Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease(COPD), Lung Diseases
- Trial name
- NCT01320566
- Testing
- AeriSeal System
- Where
- 2 sites in Israel
- Volunteers
- 18 people
- Sponsor
- Aeris Therapeutics
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.
The primary objective of this trial is to investigate the safety and tolerability of BI 1265162 in healthy male subjects following inhalative administration of multiple rising doses.
- Trial name
- NCT03576144
- Testing
- BI 1265162
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.